公开(公告)号：US12162848B2

公开(公告)日：2024-12-10

申请号：US18161184

申请日：2023-01-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Haibo Liu ,  Laura Akullian D'Agostino ,  Shoshana L. Posy ,  Annapurna Pendri ,  Swanee E. Jacutin-Porte

IPC: C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/10 ,  C07D417/12

Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.

公开(公告)号：US20240327381A1

公开(公告)日：2024-10-03

申请号：US18435117

申请日：2024-02-07

Applicant: Celgene Corporation ,  Bristol-Myers Squibb Company

Inventor： Laura Akullian D'Agostino ,  Godwin Kumi ,  Haibo Liu

IPC: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

CPC classification number: C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/00 ,  C07D471/04

Abstract: Provided herein are compounds and compositions thereof for degrading an engineered polypeptide in a cell. In some embodiments, the compounds and compositions are provided for treatment of cancer.

公开(公告)号：US20230322695A1

公开(公告)日：2023-10-12

申请号：US18161184

申请日：2023-01-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Haibo Liu ,  Laura Akullian D′Agostino ,  Shoshana L. Posy ,  Annapurna Pendri ,  Swanee E. Jacutin-Porte

IPC: C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/12 ,  C07D417/10

CPC classification number: C07D285/06 ,  A61K45/06 ,  A61P35/00 ,  C07D417/10 ,  C07D417/12

Abstract: Disclosed are compounds of Formula (I)





pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PNPT2 inhibition.